JOHNSON & JOHNSON (JNJ)
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögrens disease
Johnson & Johnson presents new data further reinforcing the role of nipocalimab in lowering the autoantibodies driving Sjögrens disease
📈 **POSITIVE** • High confidence analysis (86%) • Strong positive business development • Significant competitive advantage **Sentiment:** Positive (95%) **Content type:** Business